Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study

Fig. 1

Evolution of the eGFR during treatment and at SVR12 according to ARV regimen. (eGFR – estimated glomerular filtration rate; D1 – day 1, beginning of treatment; W2 – week 2 of treatment; W4 – week 4 of treatment; EOT – end of treatment; SVR12 – end of follow up; TDF – tenofovir; PI – protease inhibitor; Non TDF – regimens without TDF; Non-boosted TDF – regimens with TDF without boosted PI; TDF + Boosted PI – regimens with TDF and boosted PI)

Back to article page